Research programme: phosphodiesterase V inhibitors - Eisai
Latest Information Update: 17 Nov 2006
At a glance
- Originator Eisai Co Ltd
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 10 Nov 1997 Preclinical development for Thrombosis in Japan (Unknown route)